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Abstract
Batrachochytrium salamandrivorans (Bsal) has been assessed according to the criteria of the Animal
Health Law (AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the
eligibility of Bsal to be listed, Article 9 for the categorisation of Bsal according to disease prevention
and control rules as in Annex IV, and Article 8 on the list of animal species related to Bsal. The
assessment has been performed following a methodology composed of information collection and
compilation, expert judgement on each criterion at individual and, if no consensus was reached before,
also at collective level. The output is composed of the categorical answer, and for the questions where
no consensus was reached, the different supporting views are reported. Details on the methodology
used for this assessment are explained in a separate opinion. According to the assessment performed,
Bsal can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the
AHL. The disease would comply with the criteria as in sections 4 and 5 of Annex IV of the AHL, for the
application of the disease prevention and control rules referred to in points (d) and (e) of Article 9(1).
The assessment here performed on compliance with the criteria as in Section 1 of Annex IV referred to
in point (a) of Article 9(1) is inconclusive. The animal species to be listed for Bsal according to Article 8
(3) criteria are species of the families Salamandridae and Plethodontidae as susceptible and
Salamandridae and Hynobiidae as reservoirs.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL)
framework (EFSA AHAW Panel, 2017).
The present document reports the results of assessment on Batrachochytrium salamandrivorans
(Bsal) according to the criteria of the AHL articles as follows:
• Article 7: Bsal proﬁle and impacts
• Article 5: eligibility of Bsal to be listed
• Article 9: categorisation of Bsal according to disease prevention and control rules as in Annex
IV
• Article 8: list of animal species related to Bsal.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the Animal Health Law (AHL) framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of Bsal according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on
the information contained in the fact-sheet as drafted by the selected disease scientist (see Section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
A recently described fungus, Batrachochytrium salamandrivorans (Bsal), is causing several die-offs
in salamander populations in Europe (Martel et al., 2013; Spitzen-van der Sluijs et al., 2016). This
chytridiomycete fungus, which belongs to the order Rhizophydiales, produces two types of spores,
motile (zoo-)spores and non-motile encysted spores (Stegen et al., 2017), and causes the lethal skin
disease chytridiomycosis in salamanders and newts (Caudata, tailed amphibians). Chytridiomycosis due
to Bsal is characterised by multifocal superﬁcial erosions and extensive epidermal ulcerations all over
the body. Coinciding clinical signs include excessive shedding of the skin, anorexia, apathy, ataxia and
death (Martel et al., 2013). This fungus is pathogenic for most western Palearctic salamander and
newt taxa and is considered a major threat to the region’s biodiversity (Martel et al., 2013; Spitzen-van
der Sluijs et al., 2016). Salamanders can be resistant (no infection, no disease), tolerant (infection in
the absence of disease), moderately susceptible (infection resulting in clinical disease with the
possibility of subsequent recovery) or highly susceptible (infection resulting in lethal disease). It is not
known which factors underpin the susceptibility/resistance of a species. Infection experiments
demonstrated that frogs and toads are not susceptible to the disease, but can act as healthy carriers
(Stegen et al., 2017).
Bsal is believed to originate from Asia where it appears to be endemically present (Martel et al.,
2014; Laking et al., 2017) and from where it was presumably imported into Europe through the trade
of live amphibians.
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3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Fire salamander (Salamandra salamandra) is the index species, with several conﬁrmed cases of
mass mortality in the wild in Belgium, Germany and the Netherlands (Spitzen-van der Sluijs et al.,
2016). Bsal infection was implicated in the death of Alpine newts (Ichthyosaura alpestris) and smooth
newts (Lissotriton vulgaris) in Belgium, Germany and the Netherlands (Spitzen-van der Sluijs et al.,
2016). The following caudata species have died in captivity due to conﬁrmed and natural Bsal infection:
I. alpestris, Salamandra algira, S. salamandra (including the subspecies alfredschmidti, almanzoris,
bernardezi, fastuosa, gallaica, gigliolii, salamandra, terrestris, werneri), Salamandra corsica,
Salamandra infraimmaculata, Triturus macedonicus, Triturus marmoratus, Notophthalmus viridescens,
Taricha granulosa (Sabino-Pinto et al., 2015; Martel and Pasmans, 2017).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
No farmed species are known affected, only captive species (see Parameter 1) are considered
susceptible.
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Experimental infection with a single dose of 105 zoospores of Bsal resulted in 100% mortality in
specimens from the following western Palearctic species, when kept at a constant temperature of 15°C:
S. salamandra, Lissotriton italicus, L. vulgaris, I. alpestris, Triturus cristatus, Speleomantes strinatii,
N. viridescens, Taricha granulosa, Pleurodeles waltl, Salamandrina terdigitata, Neurergus crocatus,
Euproctus platycephalus. Based on phylogeny, the vast majority of western Palearctic caudata species is
considered to be susceptible to Bsal infection (Martel et al., 2014). Very few European species (e.g.
Lissotriton helveticus) appear to be resistant to infection. A recent study by Stegen et al. (2017)
demonstrated pronounced differential susceptibility between species. Highly susceptible species such as
the ﬁre salamander die even with a very low infectious dose. Disease course in the moderately
susceptible Alpine newt depends on infectious dose: a high dose results in mortality, whereas exposure
to a low dose results in highly variable scenarios, from persistent infections with eventual clearance of
the fungus, to lethal infections. Based on Bsal infection dynamics in experimental infection trials (Martel
et al., 2014), Stegen et al. (2017) predict at least the following western Palearctic caudata taxa to be
highly susceptible: all species belonging to the genera Salamandra, Euproctus, Neurergus and
Pleurodeles. Given close relatedness to the highly susceptible genus Salamandra, species of the genera
Chioglossa, Lyciasalamandra and Mertensiella are predicted to be highly susceptible as well. Based on
Bsal infection dynamics, ﬁeld data and phylogeny, species belonging to the following western Palearctic
genera are predicted to be moderately susceptible (i.e. disease outcome is dependent on infectious
dose): Lissotriton, Ichthyosaura, Triturus, Salamandrina, Speleomantes, Ommatotriton (Martel et al.,
2014; Stegen et al., 2017). Susceptibility of the genera Proteus and Calotriton cannot be estimated
based on lack of experimental and ﬁeld data and phylogenetic extrapolations.
Based on infection dynamics in experimentally infected animals and ﬁeld data, Asian caudata
belonging to the genera Tylototriton, Paramesotriton, Hypselotriton and Cynops are considered
moderately susceptible (Martel et al., 2014; Laking et al., 2017) and at least these species are
considered natural reservoirs of Bsal infection in Asia. At least some Asian salamander species belonging
to the family Hynobiidae (genera Salamandrella, Hynobius, Onychodactylus) are considered tolerant
(i.e. can be persistently infected in the absence of clinical signs and pathology) (Martel et al., 2014).
Susceptibility of American caudata species is largely unknown. Based on results from experimental
infection trials, Bsal is capable of causing mortality in species belonging to the genera Notophthalmus
and Taricha (Martel et al., 2014). Susceptibility of the largest caudata family (Plethodontidae) is
currently unknown, although Bsal was shown capable of invading the skin of at least one species
(Plethodon glutinosus) (Martel et al., 2014). Species belonging to the family Sirenidae might be
considered tolerant to infection with Bsal (Martel et al., 2014).
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
No farmed species known affected, only captive species (see Parameter 1) are considered
susceptible.
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Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
Asian caudata are generally regarded as natural hosts of Bsal and potential reservoirs. Bsal infections
in apparently asymptomatic wild Asian caudata have been conﬁrmed in Cynops pyrrhogaster,
Cynops ensicauda, Tylototriton vietnamensis, Tylototriton asperrimus, Tylototriton ziegleri, Tylototriton
uyenoi, Salamandrella keyserlingii, Paramesotriton deloustali, Hynobius nebulosus and Onychodactylus
japonicus (Martel et al., 2014; Laking et al., 2017). Bsal was found present in a museum specimen of
C. ensicauda dating from 1861 (Martel et al., 2014).
Moderately susceptible European caudata, such as I. alpestris, may equally serve as reservoir hosts
(Stegen et al., 2017): when exposed to a low infectious dose, this species can be persistently infected,
shedding signiﬁcant spore numbers, without showing any evidence of acquired immunity that protects
against re-infection.
Although originally not considered susceptible to infection, anuran (frogs and toads) have recently
been shown to be potential hosts, which can transfer infections to salamanders, acting as healthy
carriers (Stegen et al., 2017).
Bsal was shown to be present on wild small-webbed ﬁre-bellied toads (Bombina microdeladigitora)
from Vietnam and on representatives of the same species that have recently been imported in
Germany (Laking et al., 2017).
Parameter 6 – Domestic reservoir species (or family/orders)
No farmed species known affected, only captive species (see Parameter 1) are considered
susceptible.
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/Incidence
Thus far, Bsal has been demonstrated in 15 wild populations of salamanders in Belgium, Germany
and the Netherlands (Spitzen-van der Sluijs et al., 2016) and in ﬁve populations in captivity in
Germany (1), the Netherlands (2), Spain (1) and the United Kingdom (1) (Sabino-Pinto et al., 2015;
Fitzpatrick et al., 2016). The total number of wild and captive populations of salamanders in Europe is
not known.
The prevalence of Bsal in an infected salamander population varies according to the scenario.
During a Bsal outbreak in ﬁre salamanders (S. salamandra), the Bsal prevalence varied between 25%
and 63% (Stegen et al., 2017). Across a 10-day interval, the infection probability in ﬁre salamanders
was estimated at 0.33 (Stegen et al., 2017).
In Vietnam, part of the presumed region of origin of Bsal, supposed Bsal endemism coincides with
a much lower prevalence of 3% (Laking et al., 2017). Although proper prevalence studies are lacking,
the low number of Bsal positive wild salamanders in China, Japan and Thailand (17 out of 432
samples, 3.9%) corroborates low but consistent prevalence of Bsal in natural populations in Asia
(Martel et al., 2014).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
In natural infections in captivity and in the wild, case-morbidity depends on the species involved
and, at least for some species, on the infectious dose. For naturally infected animals of the genus
Salamandra (both in captives and in wild animals), case-morbidity approaches 100%. Asymptomatic
infections with Bsal in species belonging to this genus have not been conﬁrmed so far. In experimental
infection trials (Martel et al., 2014) conducted in some western Palearctic species, exposure to a single
high dose (104 spores/animal) of Bsal resulted in a case-morbidity of 100%, except for the palmate
newt (L. helveticus), which might be resistant to infection. However, exposure to a low dose (100
spores/animal) resulted in a lower case-morbidity of 6/9 in the moderately susceptible Alpine newt
(I. alpestris), while remaining 100% in the highly susceptible ﬁre salamander (Stegen et al., 2017),
suggesting case-morbidity to be a function of infectious dose in moderately susceptible species but not
in highly susceptible species (for a presumed list of highly and moderately susceptible species, see
Section 3.1.1.1).
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In the supposed natural reservoir hosts (Asian caudata species), the case-morbidity rate also
appears to depend on the infectious dose. While exposure to a single, high infectious dose resulted in
a case- morbidity rate of 100% in experimental infection trials in the species P. deloustali,
C. pyrrhogaster, Tylototriton wenxianensis and Hypselotriton cyanurus (Martel et al., 2014), natural
infections in Asian caudata belonging to the genera Paramesotriton and Tylototriton either in the wild
or in captivity could not be linked to any clinical signs or decreased body condition (Martel et al., 2014;
Laking et al., 2017). Probably, infection pressure in natural populations is low (as corroborated by the
low prevalence, see above), exposing animals to low doses of Bsal under natural conditions.
Few species were designated as tolerant: the eastern Asiatic Salamandrella keyserlingii and the
North American Siren intermedia (Martel et al., 2014), with a supposed case-morbidity rate of 0%.
Mortality
Parameter 3 – Case-fatality rate
As for the case-morbidity rate, the case-fatality rate of Bsal infections appears to be highly
dependent on host species and infectious dose. Fire salamanders show a 100% case-fatality rate,
deduced from ﬁeld data (Stegen et al., 2017), infection trials (Martel et al., 2014) and data from
outbreaks in captive animals (Martel and Pasmans, 2017). The case-fatality rate for this species is
independent of the infectious dose (Stegen et al., 2017). During an outbreak in the wild, survival of
infected ﬁre salamanders was sixfold lower than survival in non-infected salamanders (Stegen et al.,
2017), resulting in loss of over 99.9% of the population (Spitzen-van der Sluijs et al., 2016). Other
species with predicted similarly high case-fatality rates that are dose independent include the western
Palearctic genera that are listed as highly susceptible in Section 3.1.1.1. Mortality rates in Alpine newts
have been shown to be highly dependent on infectious dose, ranging from 1/5 animals exposed to a
single, low dose of Bsal to 5/5 animals exposed to a single, high dose (Stegen et al., 2017). Western
Palearctic species that have been listed as moderately susceptible in Section 3.1.1.1 probably follow a
similar pattern of dose dependent mortality. How this translates to reduced survival in the wild and
population declines is currently not clear for these moderately susceptible species.
As for the case-morbidity rate, the case-fatality rate of Bsal infections in Asian salamanders of the
above-mentioned (Section 3.1.1.2) species, probably strongly depends on infectious dose. When
exposed to a single, high Bsal dose, 4/8 C. pyrrhogaster, 3/4 P. deloustali and 3/5 H. cyanurus died.
Mortality due to Bsal has not been reported in Asian caudate, neither in the wild nor in captivity,
suggesting the case-fatality rate in natural infections to be low in these species.
Experimental infection trials and ﬁeld data suggested a very low case-fatality rate in some caudata
considered tolerant after successful infection with a single, high dose of Bsal: Salamandrella
keyserlingii and Siren intermedia (Martel et al., 2014).
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
Human infection has never been reported. To date, there are no report of zoonotic cases linked to
Bsal infection, which is considered not zoonotic.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
None reported.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
The infectious period, here deﬁned as the period during which detectable amounts of Bsal can be
demonstrated in skin swabs from infected salamanders depends on the host species, the infectious
dose and the environmental conditions (Stegen et al., 2017). Differences in the infectious period
between Bsal strains cannot be excluded at this point. When exposed to a single high dose, highly
susceptible species such as ﬁre salamanders (see Section 3.1.1.1) generally die within 15 days after
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exposure at a constant temperature of 15°C, whereas at 4°C or when exposed to a lower Bsal dose,
the duration of Bsal shedding and time to mortality are signiﬁcantly longer (Stegen et al., 2017).
Moderately susceptible species (see Section 3.1.1.1) can develop chronic infections and shed Bsal for
at least 4 months (Martel et al., 2014; Stegen et al., 2017). The duration of the infectious period in
natural populations is currently not known.
Parameter 2 – Presence and duration of latent infection period
The presence of latent infections (deﬁned as infected but not yet infectious) has not been
demonstrated yet.
Parameter 3 – Presence and duration of the pathogen in healthy carriers
The existence of healthy pathogen carriers (they are infectious but asymptomatic) has been
hypothesised to mainly occur in the region of Bsal origin, Asia (Laking et al., 2017). The duration of the
infection in healthy carriers in nature is not known. Experimental infection of species that may be healthy
carriers in the wild (Cynops, Paramesotriton) demonstrates shedding of Bsal by infected animals for up
to 4 months after exposure to a single high dose of Bsal, at a constant temperature of 15°C. Based on
infection trials, healthy carriers may be common in moderately susceptible European caudata species as
well (Stegen et al., 2017), in which Bsal was demonstrated up to more than 3 months post-exposure.
Since this long-term persistence did not result in protection against re-infection, these species may prove
suitable Bsal carriers for long periods of times (Stegen et al., 2017). Infections experiments also
demonstrated European anura (e.g. Alytes) can act as healthy carriers (Stegen et al., 2017).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
Bsal produces encysted spores that ﬂoat on water and are the infective and resistant form of the
agent in the environment, (Stegen et al., 2017). Survival has been assessed in pond water where
spores remain infectious for at least 31 days at 15°C.
Infected salamanders contaminate forest soil, which can transmit infection to na€ıve animals. Bsal
DNA was detected in forest soil up to 200 days in experimentally inoculated soil samples.
Contaminated forest soil remains infective for at least 48 h (Stegen et al., 2017).
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
Vertical transmission is likely in species that produce metamorphed offspring (Salamandra atra and
Salamandra lanzai, some S. salamandra subspecies) but this needs further investigation. Larvae of ﬁre
salamanders could not be experimentally infected with Bsal (Van Rooij et al., 2015). The tipping point
when larval salamanders become susceptible during metamorphosis is not known. Horizontal
transmission within and between caudata species has been demonstrated (Martel et al., 2014) but also
from anurans to ﬁre salamanders (Stegen et al., 2017). Transmission is likely to occur during animal–
animal contact (e.g. during courtship, territorial interactions) and indirectly by encysted spores ﬂoating
on water, motile zoospores or by contaminated forest soil (Stegen et al., 2017). Adherence of encysted
spores to inert matrices (e.g. scales on bird feet) may promote large distance spread (Stegen et al.,
2017).
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
Not applicable because no infections in humans have been reported.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
Salamanders carrying high infection loads can spread Bsal infection to na€ıve salamanders within 2 h
of cohousing (Martel et al., 2014).
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Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
Infection probability in a naturally infected ﬁre salamander population across a 10-day interval was
estimated at 0.33 (CI: 0.169–0.512) (Canessa et al., 2017).
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, where the disease is not present in the Union, the risk of its introduction
into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU
The disease has been detected in collections of captive salamanders (Germany, the Netherlands,
Spain and the United Kingdom (Sabino-Pinto et al., 2015; Fitzpatrick et al., 2016)) and in natural
populations (Belgium, Germany, the Netherlands) of salamanders. A map of the currently known
localities of affected natural populations is presented in Figure 1.
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
All occurrences presently known in natural populations are linked to mass mortality events with
population declines in at least Belgium, Germany and the Netherlands. Bsal among wild amphibians in
Europe is more widely distributed than previously known, which can either indicate recent spread of
the fungus or identiﬁed infected sites that were previously undetected (Spitzen-van der Sluijs et al.,
2016).
Risk of introduction
Parameter 3 – Routes of possible introduction
Precise routes of introduction are currently not known and thus this paragraph is largely
hypothetical. A likely route of introduction is through the trade in live, infected amphibians (Martel
et al., 2014; Laking et al., 2017). Other sources (e.g. aquatic plants) cannot be excluded, given the
presence of an environmentally resistant life stage of Bsal. Direct or indirect contact with native
caudata may result in Bsal introduction: direct contact, e.g. by release of infected, captive caudata in
garden ponds containing native caudata; indirect contact, e.g. by the use of fomites (buckets,
containers, dipnets, etc.) both for care-taking of pet caudata and in ﬁeld activities involving native
caudata or by disposal of contaminated terrarium content (soil, water) in caudata habitat.
Introduction in na€ıve regions from outbreak areas may be possible through (a) expansion via
overlapping amphibian populations (b) movement by humans of infected animals and (c) mechanical
Figure 1: Reported outbreaks of Bsal infections in natural populations of salamanders from 2013 to
2017 (author: Wouter Beukema, Ghent University)
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vectors (wildlife, humans (contaminated clothes), fomites (materials and machines used during ﬁeld
activities), contaminated water and/or soil).
Parameter 4 – Number of animal moving and/or shipment size
No ofﬁcial quantitative data are available with regard to movements of amphibians for the trade
(research, exhibitions, zoo, aquaria, etc.) within the European Union (EU) or between the EU and third
countries given the lack of a unique harmonised system commodity code identiﬁer. Of the most widely
available pet newt species (Hypselotriton orientalis), 2.3 million newts have been imported into the
USA between 2001 and 2009 (Herrel and van der Meijden, 2014). This species is a potential carrier of
Bsal. Similar numbers have likely been imported in the EU. Other Asian caudata that may be potential
carriers of Bsal and that regularly turn up in the EU trade are species of the genera Pachytriton,
Paramesotriton, Cynops, Tylototriton and Salamandrella. Approximately 156,000 salamanders, mostly
including shipments with Bsal risk, are reported to be annually imported into the USA (Yap et al.,
2015). In 2013, 21,000 individuals (Paramesotriton chinensis, N. viridescens and Cynops spp.) were
imported into the Netherlands (Spitzen-van der Sluijs et al., 2015).
Parameter 5 – Duration of infectious period in animal and/or commodity
Depending on the species, infectious dose, temperature, the duration of the infectious period is
ranging from 2 weeks to more than 4 months (see Section 3.1.1.5). Infected soil remains infective for
at least 2 days, pond water for at least 1 month (Stegen et al., 2017).
Parameter 6 – List of control measures at border (testing, quarantine, etc.)
None currently installed.
Parameter 7 – Presence and duration of latent infection and/or carrier status
The existence of asymptomatic pathogen carriers has been hypothesised to mainly occur in the
region of Bsal origin, Asia (Laking et al., 2017). The duration of the infection in asymptomatic carriers
in nature is not known. Experimental infection of species that may be asymptomatic carriers in the wild
(Cynops, Paramesotriton) demonstrate shedding of Bsal by infected animals for up to 4 months after
exposure to a single high dose of Bsal, at a constant temperature of 15°C.
Parameter 8 – Risk of introduction
The trade in live animals likely constitutes a constant threat of introduction of Bsal and other
amphibian pathogens. However, Bsal prevalence in trade is likely low. Of 2,335 samples of captive
amphibians examined, only 3 were positive for Bsal (Martel et al., 2014). It is therefore expected that
only the importation of large numbers of potential Bsal carrier species into the EU constitutes a
signiﬁcant risk.
The risk of other potential, non-amphibian routes of entry can currently not be estimated.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
Non-invasive sampling can be performed on live amphibians by collecting skin swabs for the highly
speciﬁc detection of Bsal DNA (using quantitative polymerase chain reaction (qPCR)) (Blooi et al.,
2013). The limit of detection of the fungus is 0.1 genomic equivalents (GE). The samples that can be
analysed by qPCR include swabs, toe clips and skin samples (Blooi et al., 2013). The qPCR is able to
detect the fungus before the animal shows clinical signs of disease (Martel et al., 2014).
Alternatives to qPCR include histopathology of skin, immunohistochemistry using polyclonal
antibodies or the use of a recently developed lateral-ﬂow technique (Dillon et al., 2017). These
methods fail to discriminate between Bsal and its sister species Batrachochytrium dendrobatidis (Bd)
and have a lower sensitivity than the qPCR method (Dillon et al., 2017).
Control tools
Parameter 2 – Existence of control tools
Bsal in captive caudata can be controlled using a combination of proper quarantine and entry
control for Bsal of any newly acquired animal. Quarantine should consist of a period of at least
40 days, preferably at a Bsal permissive temperature (optimum of 15°C) (Martel et al., 2013) during
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which overall health of the animal should be assessed and a skin swab should be collected for
quantiﬁcation of Bsal DNA using qPCR during the last week of the quarantine period (Blooi et al.,
2015b). During this period, all materials that have come into contact (directly or indirectly) with the
quarantined animal should be properly disinfected. This can be done by chemical decontamination. An
overview of effective disinfection protocols is given in Table 1. Hydrogen peroxide shows poor activity
against Bsal. Heat treatment is to be expected to result in fast killing of all life stages of Bsal but needs
further study. The fungus poorly tolerates high temperatures: Bsal cultures are killed after incubation
for 5 days at 25°C (Blooi et al., 2015a). If Bsal responds to heat as its sister species Bd, exposing
materials to 60°C for 5 min or 100°C for 1 min should be efﬁcient (Johnson et al., 2003).
If salamanders are infected by Bsal in captivity, the infection can be effectively treated either using
temperature treatment (Blooi et al., 2015b) or chemotherapeutics (Blooi et al., 2015a), which are
capable of clearing the infection. Collections of captive caudata can be cleared from Bsal infection
(Martel and Pasmans, 2017) by keeping the infected salamanders at 25°C for 10 days (Blooi et al.,
2015a). For salamander species that do not tolerate these relatively high temperatures, an alternative
consists on the combination of topical application of voriconazole with polymyxin E and keeping the
infected salamanders at 20°C for 10 days (Blooi et al., 2015a). Post-treatment assessment of Bsal
absence is obligatory and the treatment may need repeating until total clearance.
Controlling Bsal in natural populations of salamanders is currently limited to measures that prevent
Bsal introduction. No curative measures are available to mitigate Bsal in natural caudata populations
once the pathogen is established. As an emergency measure to safeguard highly valuable populations
from extinction, the development of captive assurance colonies is recommended (Stegen et al., 2017).
Table 1: Minimal exposure time for 100% killing of Bsal spores and sporangia at room temperature
(Van Rooij et al., 2017)
Disinfectant Concentration
Minimal exposure time
for 100% killing of Bsal
Ethanol (EtOH) 70% 30 s
Disolol® Undiluted 30 s
Hibiscrub® 0.25, 0.5, 0.75% 30 s
Chloramine-T® 0.5% 5 min
1% 2 min
Bleach 1:5 dilution 5 min
4% 30 s
Kickstart® 0.05% 5 min
0.1% 2 min
Potassium permanganate (KMnO4) 1% 10 min
2% 5 min
Virkon S® 0.5% 5 min
1% 2 min
Dettol medical® 1:20 dilution 5 min
Biocidal® Undiluted 30 s
Safe4® Undiluted 30 s
F10® 1:100 dilution 30 s
1:250 dilution 30 s
1:500 dilution 30 s
1:1,000 dilution 30 s
Sodium chloride (NaCl) 10% 10 min
Bsal: Batrachochytrium salamandrivorans.
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3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
Currently
In wild populations: Belgium, Germany, the Netherlands (Spitzen-van der Sluijs et al., 2016).
In captive salamanders: Germany, the Netherlands, Spain, the United Kingdom, (Fitzpatrick et al.,
2016; Sabino-Pinto et al., 2015).
Potential
In wild populations: recent modelling of Bsal infection and disease across Europe based on its
native niche (Beukema et al., 2017) predicts the potential of Bsal to affect caudata populations in all
European nations, with high suitability of regions that are of special conservation interest for caudata
(regions with high caudata endemicity such as the Iberian peninsula, Corsica and Sardinia, Italy and
the Alps and the countries bordering the Adriatic sea).
In captive salamanders: Bsal has the potential to spread between collections among all European
countries (and beyond), probably mainly through trafﬁc in live caudata.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
Not applicable because salamanders are not used as production animals.
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
No zoonotic cases have been reported.
Bsal most probably does not infect humans, given the low thermal preference of the fungus.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
In highly susceptible hosts and at permissive temperatures, Bsal infections invariably result in a
lethal, ulcerative skin disease (Figure 2), with morbidity and mortality approaching 100% (Stegen
et al., 2017) and over 99.9% reduction of the population size (Spitzen-van der Sluijs et al., 2016).
In moderately susceptible hosts, the infection results in skin infection, either or not coinciding with
cutaneous disease (skin ulceration) and potentially leading to death (Martel et al., 2014; Stegen et al., 2017).
Tolerant hosts do not show obvious signs of reduced welfare after infection.
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3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
Bsal is currently expanding its range, approaching several species listed as endangered by IUCN
and/or included in the Habitat’s directive. Niche modelling demonstrates that most European species
that are estimated susceptible to Bsal are at risk of population crashes (Beukema et al., 2017). A
tentative list of species, threatened by Bsal, with their established or estimated level of susceptibility
(see Section 3.1.1.1) is provided in Table 2. Consequences for the demography and biodiversity of
natural populations are not entirely clear yet but probably of high relevance.
Figure 2: Immunohistochemical staining (left panel; author: An Martel, Ghent University) of formalin-
ﬁxed skin tissue of a dead ﬁre salamander (right panel; author: Frank Pasmans, Ghent
University) from Robertville, Belgium. The picture shows intra-epidermal proliferation of Bsal
(brown structures), resulting in extensive skin ulceration and subsequent death
Table 2: Tentative list of presumed moderately or highly susceptible European caudata species
either included in Annex IV of the Habitats Directive and/or listed in the European Red List
of Amphibians
Species name
Inclusion in Annex IV,
Habitats directive
IUCN European
Red List
Estimated susceptibility
Lyciasalamandra helverseni Yes VU High
Atylodes genei Yes VU Moderate
Calotriton arnoldi Yes CR Unknown
Calotriton asper Yes NT Unknown
Chioglossa lusitanica Yes VU High
Euproctus montanus Yes LC High
Euproctus platycephalus Yes EN High
Lissotriton italicus Yes LC High
Lissotriton montandoni Yes LC Unknown
Pleurodeles waltl No NT High
Proteus anguinus Yes VU High
Salamandra algira* No VU High
Salamandra atra Yes LC High
Salamandra lanzai Yes VU High
Salamandrina perspicillata Yes LC Moderate
Salamandrina terdigitata Yes LC Moderate
Speleomantes ambrosii Yes NT Moderate
Speleomantes ﬂavus Yes VU Moderate
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Parameter 2 – Mortality in wild species
In natural populations, mortality due to Bsal has been conﬁrmed extensively in ﬁre salamanders
(S. salamandra), with crashes reducing the populations by over 99.9% (Spitzen-van der Sluijs et al.,
2016). Fire salamander populations undergo a 90% decline within 6 months after the onset of the
disease (Stegen et al., 2017). Mortality has been observed in newts (I. alpestris, L. vulgaris) but the
impact of Bsal on natural newt populations is currently unclear.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
Bsal is a wildlife pathogen causing extinction events in ﬁre salamander populations (Martel et al.,
2013; Stegen et al., 2017) and probable extinction in several highly susceptible and threatened
European species (see Section 3.1.1.1 and Table 1). For persistence in the environment, see
Section 3.1.1.5 Parameter 4.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
This is a recently discovered pathogenic fungus (Martel et al., 2013), recently added to the OIE list
of aquatic animal diseases.1 Further, it is not included in the Center for Food Security and Public Health
(CFSPH) list of Bioterrorism and High Consequence Pathogen (CFSPH, 2017).
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
It is not listed.
Parameter 3 – Included in any other list of potential bio- agro-terrorism agents
It is not listed.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
In general, control measures are applicable to captive animals, to a lesser or no extent to wild
animals.
Species name
Inclusion in Annex IV,
Habitats directive
IUCN European
Red List
Estimated susceptibility
Speleomantes imperialis Yes NT Moderate
Speleomantes italicus Yes NT Moderate
Speleomantes sarrabusensis Yes VU Moderate
Speleomantes supramontis Yes EN Moderate
Speleomantes strinatii Yes NT Moderate
Triturus carnifex Yes LC Moderate
Triturus cristatus Yes LC Moderate
Triturus dobrogicus Yes NT Moderate
Triturus ivanbureschi Yes Moderate
Triturus macedonicus Yes Moderate
Triturus marmoratus Yes LC Moderate
Triturus pygmaeus Yes NT Moderate
CR: critically endangered; EN: endangered; VU: vulnerable; NT: near threatened; LC: least concern.
*: It does not naturally occur in the EU.
1 http://www.oie.int/index.php?id=171&L=0&htmfile=chapitre_batrachochytrium_dendrobatidis.htm
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3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
No OIE certiﬁed diagnostic tools are available. The only available qPCR protocol currently routinely
used internationally as the reference standard for Bsal detection in skin and skin swabs is the one
developed by Blooi et al. (2013) that has been used in several laboratories providing consistent results
(Sabino-Pinto et al., 2015; Fitzpatrick et al., 2016; Spitzen-van der Sluijs et al., 2016). The diagnostic
characteristics of this test has been recently evaluated by Thomas et al. (submitted) and, despite some
limitations linked to the limited sample size used for its validation and being based on a single
laboratory study, study results are reported below under ‘effectiveness’.
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
The diagnostic sensitivity (DSe), diagnostic speciﬁcity (DSp) and reproducibility of the Bsal qPCR
developed by Blooi et al. (2013) were evaluated using DNA samples from 26 experimentally infected
and 12 non-infected salamanders in three external labs (see above under ‘availability’). Exact binomial
conﬁdence intervals were obtained using the test results in the three laboratories using the method of
Clopper–Pearson (Brown et al., 2001). The DSe was 96% (95% IC: 80.4–99.9%) in one laboratory and
100% (95% IC: 86.6–100%) in two laboratories. The DSp in all three laboratories was 12 out 12
(100%; 95% IC: 73–100) (estimates were based on data used in Thomas et al. (submitted), i.e. the
dichotomous outcome of the test performed in three different laboratories).
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
In live animals, non-invasively collected samples (skin swabs) can be easily and quickly collected
(Blooi et al., 2013; Martel et al., 2013, 2014). A cotton-tipped swab should be rubbed ﬁrmly over the
abdominal area, ventral tail and foot 10 times each and subsequently stored dry, and preferably frozen
to avoid DNA degradation.
In dead animals, qPCR on skin tissue can be combined with histopathology of the skin and, if
available, immunohistochemistry (Van Rooij et al., 2015; White et al., 2016).
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
None.
Parameter 2 – Availability/production capacity (per year)
Not applicable since no vaccines have been developed.
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
Vaccination of caudata of Bsal does not seem to be a promising measure for future development.
Repeated cycles of experimental infection/treatment in two salamander species (ﬁre salamanders and
Alpine newts) did not induce any obvious protection against re-infection and clinical disease (Stegen
et al., 2017).
Parameter 4 – Duration of protection
Not applicable since no vaccine is available.
Feasibility
Parameter 5 – Way of administration
Not applicable since no vaccine is available.
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3.1.4.3. Article 7(d)(iii) Medical treatments
Availability
Parameter 1 – Types of drugs available on the market
Only infected animals in captivity can be efﬁciently treated. The treatment of choice consists of
heat treatment (25°C for 10 days) (see Section 3.1.1.8 Parameter 2). Cocktails of drugs (topical
treatment combining polymyxin E submersion baths and voriconazole sprayed twice a day for 10 days
at an ambient temperature of 20°C) can be used (Blooi et al., 2015b).
Parameter 2 – Availability/production capacity (per year)
Not applicable since temperature treatment is the preferred option. Voriconazole is preferably used
as the intravenous formulation for humans and is not registered for use in amphibians. Polymyxin E is
widely used in veterinary medicine.
Effectiveness
Parameter 3 – Therapeutic effects on the ﬁeld (effectiveness)
Heat and antimicrobial treatment can be 100% effective in eliminating Bsal infection in captive
caudata. Since the number of Bsal strains available is currently very limited; however, it is not known
to which extent these treatment protocols are applicable to Bsal in general (for example, a strain with
a higher thermal tolerance may survive the heat treatment protocol; sensitivity to antimicrobial drugs
may vary between strains).
Feasibility
Parameter 4 – Way of administration
For caudata species that tolerate the relatively high temperature of 25°C, this is by far the
preferred method. Animals can be treated in large groups both in terrestrial and aquatic species, there
is no impact on the environment (contamination with antimicrobial drugs) and this procedure may be
suitable during quarantine of imported caudata species that tolerate this temperature. Among
European species, the ones that could tolerate such high temperature (> 25°C) are at least
Triturus dobrogicus, usually kept at 15°C, with critical thermal maximum (CT max) of 36.8°C  0.2
(Gvozdik et al. 2007); Ommatotriton vittatus (kept at 10°C) with CT max of 34.2°C (Warburg 1971)
and S. infraimmaculata (kept at 10°C) with CT max of 32.5°C (Warburg 1971).
Antimicrobial treatment is laborious, consisting of a labour-intensive protocol of bathing (polymyxin E),
spraying (voriconazole) and housing at a temperature of 20°C. Treatment ﬂuids that are disposed of may
end up in the environment.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
Biosecurity measures should be aimed at
1) preventing further introduction of Bsal (and other amphibian pathogens) into the EU
No ofﬁcial measures currently exist. Prevention of Bsal introduction may be achieved by a
combination of quarantine joined with obligatory entry control of any amphibian entering the EU
(EFSA, 2017). An importation ban is an alternative approach but may drive amphibian movements
across borders. The trade is well aware of Bsal and has issued guidelines for their members. In a joint
report of the Ornamental Fish International, Ornamental Aquatic Trade Association, the Reptile and
Exotic Pet Trade Association and the Pet Industry Federation, they support quarantine measures and
testing of animals for entry control, restricting salamander movements for potential Bsal hosts, a
tracking system for captive caudata, the implementation of biosecurity measures and raising public
awareness (Joint Response, 2017). Effective prevention, however, requires knowledge of the route of
entry of Bsal in Europe. Although trafﬁc in live amphibians is generally considered a major route,
further studies about entry routes of chytrid fungus infections are needed.
2) preventing introduction of Bsal in na€ıve regions from outbreak regions
To prevent spill-over from Bsal from outbreak areas into na€ıve areas, ﬁeld protocols have been put
in place, which emphasise proper disinfection of all materials between amphibian populations visited.
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The implementation of these protocols is obligatory for ﬁeld workers who ask for permits in Flanders
(see below) and similar biocontrol measures are advised but not ofﬁcially imposed in the Netherlands
(advised by RAVON Foundation – Reptile, Amphibian and Fish Conservation Netherlands) and Germany
(advised by Trier University). In Flanders, a perimeter of 1 km has been deﬁned around a Bsal locality
(Duffel). No permits are being delivered by the authorities for ﬁeld activities within this perimeter.
Summary of measures imposed by the Flemish government (ANB) for ﬁeld activities in response to
the emergence of Bsal:
• Manipulation of amphibians is allowed only when strictly necessary
• Either disposable vinyl gloves should be worn when handling amphibians or hands should be
disinfected after handling
• All materials used must be cleaned and disinfected between sites and preferably on-site,
including clothes that made contact with the environment. Virkon 1% should be used as
disinfectant. Alternatively, heating at 60°C for 30 min is accepted. This measure also applies to:
 amphibian monitoring activities all activities in amphibian habitats (not necessarily limited to activities pertaining to
amphibians)
• Vehicles should be parked on paved roads wherever possible
• Dead or ill amphibians should only be handled with gloves
• For actions targeted at reducing road mortality during spring migration, one dedicated set of
material per site should be used
• For education oriented projects, only a single freshwater locality per day can be visited
• For monitoring projects, all materials must be cleaned and disinfected between sites as
mentioned before
• For all activities in amphibian habitats (not necessarily limited to activities pertaining to
amphibians) all materials must be cleaned and disinfected between sites as mentioned before.
Public education by means of information panels informs visitors to outbreak sites in some areas
(for example Robertville in Wallonia, Bunde in the Netherlands: Figure 3). Raising public awareness
through general media is important to alert people when dead amphibians are encountered in the ﬁeld
and to encourage using proper hygienic measures before and after visit to amphibian populations. In
the countries were Bsal outbreaks are currently ongoing in natural populations, all amphibians are
strictly protected by law.
Figure 3: Information panel at the entrance of the outbreak site in Robertville (Belgium) in French,
German and Dutch (author: Frank Pasmans, Ghent University)
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Preferably, outbreak sites should be closed for recreational use and for any non-essential activity to
limit opportunities of Bsal spread through human activities.
The fast identiﬁcation of a Bsal outbreak in the ﬁeld and the instalment of an early warning system
should prevent Bsal spread and introduction in na€ıve regions from outbreak regions. A network of
diagnostic laboratories is currently being built across Europe in the framework of EC Tender ENV.B.3/
SER/2016/0028. An early warning system (passive and sometimes active monitoring) is in place in
Belgium, Germany and the Netherlands and this will be implemented across the EU in the framework
of the above mentioned EC Tender ENV.B.3/SER/2016/0028. Passive monitoring consists of the
detection and collection of suspect cases/mortality by any stakeholder visiting amphibian habitats (ﬁeld
workers, recreational users, scientists, hunters, etc.), followed by speciﬁc examination for the presence
of Bsal. Passive monitoring appears as the most appropriate method for Bsal detection in caudata
species as the infection is associated with mortality. Active monitoring consists of detecting Bsal in
swab samples in amphibian populations.
According to different minimum expected prevalences and population sizes and assuming 100%
test Sp, the sample size needed to provide the 95% probability of detecting at least one positive
animal is reported in Table 3. Since the test Se was derived using experimentally infected animals, it
may be possible that this value may be lower when used in the ﬁeld with naturally infected
populations. For this reason and with the aim of being conservative, 80.4% Se, the lower conﬁdence
bound computed using the data from one of the three laboratories (the one with the lowest sensitivity)
reported in Section 3.1.4.1, has been used to estimate the sample sizes as in Table 3. Additionally, it
needs to be noted that it is not clear whether there exist other fungi or organisms in natural
populations that could cross-react with Bsal, in which case they would give false positive test results,
resulting in speciﬁcity lower than 100%. In the estimates provided in Table 3, the effect of dealing
with different wild animal species not homogenously distributed in space has not been taken into
account. Therefore, active monitoring, if not designed according to the different factors affecting the
population size and the geographical distribution of the host and the pathogen, could have very low
probability in detecting Bsal in the salamander populations.
The design prevalence of 1%, 3% and 10% are chosen as examples. Where the disease has an
epidemic behaviour as currently in Europe, the prevalence in outbreak area can be expected to be
> 10%, whereas 3% could be considered as the minimum expected prevalence value registered in
endemic areas as in Asia (see Section 3.1.1.2), thus such a design prevalence could be used for
limiting the introduction of the disease into EU from endemic countries, e.g. in consignment of
salamanders from Asia.
Table 3: Sample size needed for providing the 95% probability of detecting at least one positive
animal according to different population sizes and minimum expected prevalence,
assuming 80% test Se and 100% test Sp (NA = not applicable)
Population size
Minimum expected prevalence
1% 3% 10%
19 NA* NA* 19
62 NA* 62 29
186 186 96 34
200 194 98 34
250 218 102 34
300 237 106 35
350 251 108 35
400 263 110 35
450 273 111 35
500 281 112 35
550 288 113 35
600 294 114 36
100,000 (inﬁnite population size) 373 124 36
In bold, the sample size threshold for having 95% probability of detecting at least one infected animals at 1%, 3% and 10%
prevalences.
*: NA: not applicable as the sample size does not allow demonstrating 95% probability absence of the diseases.
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Similarly, in the graph in Figure 4, it is possible to visualise the trend of sample size according to
increasing population size and to the different minimum expected prevalence.
Several organisations (e.g. in Belgium Natuurpunt, Natagora, Ghent University and the Flemish and
Wallonian government; in the Netherlands RAVON, the Dutch government) collaborate in the
establishment of regional hotlines, where suspect cases can be reported.
Ex situ conservation has been proposed as the sole effective measure in preventing Bsal infected
populations of highly susceptible species from going extinct (Stegen et al., 2017). A captive assurance
colony of the remaining ﬁre salamanders exists in the Netherlands (collaboration between zoos,
RAVON and the Dutch government) and is envisaged in Flanders in case Bsal would infect local ﬁre
salamander populations.
3) preventing Bsal spread between captive and natural caudata populations
No ofﬁcial measures currently exist. Any direct or indirect contact between captive and natural
caudata populations must be avoided. If European populations of captive caudata would be screened
for the presence of Bsal, with subsequent follow-up to clear existing infections, this, combined with
proper entry control and quarantine, may assure Bsal to be absent from captive salamanders,
excluding a potentially important source of Bsal for native salamanders.
Raising public awareness by means of presentations on meetings and publications in journals that
reach a terrarium audience has been intensively pursued: terrarium keepers, associated with the
hobby clubs seem well aware of the problem. The largest association of terrarium enthusiasts in
Europe (the Deutsche Gesellschaft f€ur Herpetologie und Terrarienkunde (DGHT)) has published a
position paper on Bsal (DGHT, 2016) in which they advise their members to strictly adhere to
biosecurity measures, monitor their captive caudata, urge for fast diagnostics and treatment,
quarantine and entry control to limit spread of Bsal through captive caudata. The Dutch
‘Salamandervereniging’, comprising caudata keepers only, advertises similar measures to their
members. Overall, the terrarium keepers are highly motivated to eliminate any Bsal infection from
captivity given the near total destruction of susceptible species in captive caudata collections once Bsal
entered (Martel and Pasmans, 2017).
Building veterinary capacity across Europe to increase the likelihood that Bsal infections in captivity
are diagnosed and treated correctly and quickly should be considered a priority. A network of
diagnostic laboratories is currently being built across Europe in the framework of the EC Tender
ENV.B.3/SER/2016/0028.
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
Biosecurity measures are expected to be crucial in preventing pathogen introduction in natural and
captive amphibian populations in na€ıve regions.
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Figure 4: Sample size by population size for providing the 95% probability of detecting at least one
positive animal according to different minimum expected prevalence (1%, 3% and 10%),
assuming 80% test Se and 100% test Sp
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Feasibility
Parameter 3 – Feasibility of biosecurity measures
Feasibility depends on the measures and on the willingness of authorities to implement these
measures. Overall, the biosecurity measures proposed above should be easy to implement but conﬂicts
may arise with regional interests (e.g. closure of recreational areas). A further complicating factor is
the involvement of non-professionals (the general public, terrarium keepers, and volunteers). For
proper implementation of the biosecurity measures, at least the following stakeholders should be
motivated to comply with biosecurity measures:
• any person professionally or voluntarily involved in ﬁeld activities in amphibian habitats (e.g.
research, education, habitat restoration, etc.);
• trade through the entire commercial chain;
• captive collection holders (zoos, private keepers, ex situ conservation programmes);
• any person visiting outbreak sites (several outbreak sites are in important touristic sites that
are heavily frequented for recreational use),
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
None currently in place.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
Restriction of animal movement is applicable to captive animals and it is highly likely to limit spread
of Bsal if properly implemented. Release of captive animals in natural amphibian populations should be
avoided, unless the released animals have been produced in the framework of a strictly monitored and
designed conservation programme taking all necessary biosecurity measures into account, including
testing for known amphibian diseases before release. In this respect, the sale of amphibians in garden
centres for release in garden ponds should be strongly discouraged or even forbidden.
For amphibians in trade, animal movement of only Bsal-free animals would help in preventing the
introduction and further spread of this pathogen.
In case Bsal would be detected in captive salamanders, all movements of animals to and from the
infected collection should be strictly avoided until successful treatment and clearance of the fungus
from the collection. A generalised transport restriction of salamanders between captive sites is
extremely difﬁcult to monitor, since many species can be easily transported in small containers via any
transportation means.
For natural populations, any movement of animals between localities (e.g. for translocation,
reintroduction, reinforcement) should preferably be restricted to cases with a clear conservation beneﬁt
based on sound scientiﬁc evidence. In case of movement, all animals to be moved should be clinically
healthy and should be free of at least the amphibian pathogens Bsal, Bd and ranaviruses.
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
Restriction of animal movement should be feasible especially in professional organisations (trade,
zoos, conservation-oriented organisations). Feasibility in non-professionals (e.g. terrarium keepers)
depends on implementation (e.g. efforts spent on continuously raising public awareness) and probably
also on the level of the keeper: knowledgeable private keepers associated with hobby clubs or internet
fora/social media groups are more likely to be informed than non-knowledgeable people buying newts
in pet shops for an ornamental aquarium. This latter category is important since the vast amount of
Asian newts imported (H. orientalis, a potential Bsal carrier) most probably ends up with this latter
group of keepers who are more difﬁcult to reach.
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3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
None. Caudata can be killed by various methods. Injection (intravenously, intracoelomically,
intralymphatically) of sodium pentobarbital is deemed acceptable (AVMA, 2013). Topical application
using bathing solutions of anaesthetics such as tricaine methanesulfonate or benzocaine are equally
considered acceptable and allow euthanising groups of animals (AVMA, 2013). Although previously
deemed unacceptable, recent evidence suggests cooling and subsequent freezing of amphibians to
result in painless death (Shine et al., 2015) and this method can be applied for mass euthanasia.
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
Killing animals could be carried out at three levels:
• Bsal-infected animals in trade: killing in combination with biosecurity measures would
effectively stop spread from these animals. However, given the relatively ease and efﬁcacy of
the existing treatments and presence of diagnostic tests, treatment should be the preferred
option over killing.
• Bsal-infected animals in captive collections: idem as for animals in trade.
• Bsal-infected animals in natural populations: in theory, removing all infected (or even all)
animals from a natural population in combination with biosecurity measures would limit the
spread of the disease. However, the presence of non-caudata and environmental Bsal
reservoirs (Stegen et al., 2017), combined with a low probability of capturing all caudata in a
population, renders success of culling all infected animals in natural populations highly unlikely
(Stegen et al., 2017). Indeed, given its host population density independent epidemiology,
removing only a proportion of a population is highly unlikely to stop an outbreak (Stegen et al.,
2017).
Feasibility
Parameter 3 – Feasibility of killing animals
Feasibility of killing animals in trade or in captive collections can be considered high but may be
strongly opposed by public opinion.
Feasibility of killing a sufﬁcient number of animals in natural populations can be considered not
feasible for the reasons mentioned above.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
Most dead captive caudata carcasses probably end up in the dustbin together with household
waste (although in theory this is generally prohibited). If this waste is subsequently treated (e.g.
incineration), this will effectively kill Bsal. When disposed of in open air waste dumps, this might hold a
theoretical risk of pathogen spread.
A proper disposal option for caudata carcasses and associated wastes is commercial ﬁxed plant
incineration. Disposal of carcasses should include a procedure that inactivates Bsal (and preferably
other amphibian diseases such as Bd and ranaviruses), which can be achieved either by thermal
treatment (at least 30 min at 60°C) or chemical disinfection (see above).
Carcasses and associated wastes (e.g. soil or water from terraria) should not be disposed of in
nature without prior decontamination, since this may result in spill-over of Bsal to native amphibians.
Effectiveness
Parameter 2 – Effectiveness of disposal option
Proper disinfection procedures should result in safe and effective disposal.
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Feasibility
Parameter 3 – Feasibility of disposal option
High, since caudata typically are small animals of less than 20 cm, relatively small volumes have to
be disposed off. Feasibility of disposal of large quantities of contaminated terrarium content can be an
issue.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
Very difﬁcult to quantify and highly depending on the scenario:
• For trade: combination of entry control, quarantine and, if necessary, treatment. The volume
of traded caudata represents a minor proportion of the trade (Gilbert et al., 2016). Costs for
Bsal-free caudata in the trade can be included in the price setting of the animals. Overall,
caudata are relatively inexpensive (customer prices generally between EUR 10 and 100 per
animal). The Asian species traded in the largest numbers and a possible vector for Bsal
(H. orientalis) typically sells for low prices (around EUR 10 per animal, see Figure 5).
• For keepers of caudata: combination of entry control, quarantine, biosecurity measures (e.g.
disinfection of terrarium contents) and, if necessary, treatment. A diagnosis based on the
combination of necropsy, histopathology and qPCR costs approximately EUR 100 at the
diagnostic centre of Ghent University, allowing group diagnosis of the disease in an infected
collection. Depending on the diagnostic laboratory, follow-up of infected collections using qPCR
on skin swabs costs between EUR 20 and 50 per swab. The preferred method of treatment
(heat) is a low-cost treatment. Currently, keepers of caudata (zoos, conservation programmes
and private keepers) have shown motivation to cover these costs, given the far-reaching
implications of Bsal infection for the collection’s health.
• For natural populations: preventive biosecurity measures as mentioned above do come with a
cost (disinfection procedures, public education, early warning system, closure of recreational
areas). Active and passive monitoring is currently being supported by governments (Dutch,
German and Belgian governments). Costs for passive monitoring are limited to the
transportation of carcasses and diagnostic procedures. Costs for active monitoring cover ﬁeld
activities (sampling) and diagnostic procedures. Costs for captive assurance colonies depend
on the strategy followed: from mere maintenance of individuals ex situ (requiring staff,
infrastructure and material costs) to manage breeding programmes (requiring the
same + genetic management).
Figure 5: Hypselotriton (‘Cynops’) orientalis for sale in a garden centre. This species is the most
commonly imported Asian salamander and a potential carrier of Bsal (author: Frank
Pasmans, Ghent University)
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Parameter 2 – Cost of eradication (culling, compensation)
• For captive animals: depending on price setting for compensation/animal. Group treatment or
euthanasia for amphibians is relatively low cost. Obligatory follow-up with skin swabs after
treatment represents the major cost.
• For natural populations: eradication is currently not considered an option for both technical
and ethical concerns (Stegen et al., 2017).
Parameter 3 – Cost of surveillance and monitoring
Surveillance and monitoring, both in animals in captivity and the wild, can be done using qPCR on
skin swabs. Apart from the costs associated with collecting the samples, costs of qPCR as mentioned
above.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
Currently, the USA has banned the importation of caudata based on the risk of introduction of Bsal
(US Fish and Wildlife Service, 2016). If the EU would install an importation ban or restriction, this is
likely not to result in signiﬁcant economic losses (although, as mentioned before, this cannot be
accurately estimated, given the lack of data with regard to quantities traded).
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector)
This cannot be quantiﬁed properly but caudata probably represent a minor proportion in the trade.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
Probability of societal acceptance of implementation of mitigation measures is expected to be high,
even desired, since mitigation of Bsal promotes animal health and welfare and biodiversity
conservation. Acceptance will probably depend on the measures imposed and on the explanation/
rationale provided for the measures. While biosecurity measures like entry control, disinfection, public
education, restricting trade and curative treatments will probably be readily accepted, culling (certainly
of wild animals) may provoke a strong and negative response.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
The control measures (biosecurity and treatment) increase welfare of captive caudata since this
directly improves animal health. Temperature control should not involve caudata species that cannot
tolerate high temperature (25°C check) (see Section 3.1.4.3 parameter on treatment). However, there
is a lack of knowledge on the impact of the procedures of treatment on the welfare of salamanders.
Parameter 2 – Wildlife depopulation as control measure
Although culling of all caudata in an affected wild community might be theoretically a defendable
option in an attempt to eliminate Bsal from an infected area, this comes with several, major problems
such as: (see also Section 3.1.5.2 above):
• very low probability that depopulation is effective, given the estimated low feasibility of
capturing all individuals present at a site;
• the presence of persistent forms of Bsal in the environment creating an ongoing risk;
• societal acceptance is most likely very low and adverse reactions from the public, academia
and nature conservation organisations can be expected;
• legal issues may prevent depopulation: many European amphibians are strictly protected at
national and European level.
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3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
Manufacture and use of disinfectants in the EU must comply with Regulation (EU) No 528/20122.
Speciﬁc derogations for the use of disinfectants in the ﬁeld are necessary (e.g. the use of Virkon, currently
routinely used). Disposal of disinfectants in the environment (e.g. chlorine) should be strongly discouraged.
Biodiversity
Parameter 2 – Mortality in wild species
The relevance of Bsal in the EU is its potential to cause signiﬁcant mortality in many wild species of
caudata (see above). While mortality in captive species can be counteracted, mortality in wild caudata
can currently not be mitigated. Bsal can drive amphibian species to local extinction. This may lead to
loss of biodiversity, at least at local level (Martel et al., 2014; Stegen et al., 2017).
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about Bsal (Table 4). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 4: Outcome of the expert judgement on the Article 5 criteria for Batrachochytrium
salamandrivorans
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist in
the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due to
its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal health,
or poses or could pose a signiﬁcant risk to public health due to its zoonotic character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger to
public and/or animal health in the Union
N
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
N
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for the
purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment, including
biodiversity, of the Union
Y
Colour code: green = consensus (Yes/No).
2 Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available
on the market and use of biocidal products. OJ L 167, 27.6.2012, p. 1–123.
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3.2.1. Outcome of the assessment of Batrachochytrium salamandrivorans
according to criteria of Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 4, Bsal complies
with all criteria of the ﬁrst set and with two criteria of the second set, therefore it is considered eligible
to be listed for Union intervention as laid down in Article 5(3) of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about Bsal (Tables 5, 6, 7, 8 and 9). The expert judgement was
based on ICBA approach described in detail in the opinion on the methodology. Experts have been
provided with information of the disease fact-sheet mapped into Article 9 criteria (see supporting
information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion
of Article 9, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 10. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 5: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for Batrachochytrium salamandrivorans (CI: current impact; PI:
potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present only in a very limited part of the territory of
the Union
NC
2.1 The disease is highly transmissible NC
2.2 There are possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
Y
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
Y
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5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
Y
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
Y
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
Table 6: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for Batrachochytrium salamandrivorans (CI: current impact; PI:
potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are
free of the disease
NC
2.1 The disease is moderately to highly transmissible NC
2.2 There are possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
Y
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
Y
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
Y
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
Y
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
AHL assessment on Batrachochytrium salamandrivorans (Bsal)
www.efsa.europa.eu/efsajournal 26 EFSA Journal 2017;15(11):5071
Table 7: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for Batrachochytrium salamandrivorans (CI: current impact; PI:
potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character OR in aquatic animals several Member States or zones of the Union are free
of the disease
Y
2.1 The disease is moderately to highly transmissible NC
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss OR in aquatic
animals the disease may result in high morbidity and usually low mortality AND often
the most observed effect of the disease is production loss
N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
Y
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
Y
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
Y
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
Y
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
Table 8: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for Batrachochytrium salamandrivorans
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated
by measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
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3.3.1. Non-consensus-questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of Tables 10–12. The
proportion of Y, N or ‘na’ answers are reported, followed by the list of different supporting views for
each answer.
Reasoning supporting the judgement
Supporting Yes for 1 (cat. A):
• The distribution of Bsal is currently very limited, and its presence is still not endemic, although
very likely to become, since it will be difﬁcult to avoid spread further given multiple outbreaks
in wild species already in diverse locations.
Supporting Yes for 1 (cat. B):
• It is present in wild populations in Belgium, Germany, the Netherlands (Spitzen-van der Sluijs
et al., 2016) and in captive salamanders in Germany, the Netherlands, Spain and the United
Kingdom (Fitzpatrick et al., 2016; Sabino-Pinto et al., 2015).
• It appears that the disease can maintain itself in the population without introduction from
outside.
Table 9: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for Batrachochytrium salamandrivorans
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal
welfare, human health, the economy, society or the environment (If a disease fulﬁls the
criteria as in Article 5, thus being eligible to be listed, consequently category E would
apply.)
Y
Colour code: green = consensus (Yes/No).
Table 10: Outcome of the expert judgement related to criterion 1 of Article 9
Question Final outcome
Response
Y (%) N (%) na (%)
1 (cat. A) The disease is not present in the territory of the
Union OR present only in exceptional cases
(irregular introductions) OR present only in a
very limited part of the territory of the Union
NC 50 50 0
1 (cat. B) The disease is present in the whole OR part
of the Union territory with an endemic
character AND (at the same time) several
Member States or zones of the Union
are free of the disease
NC 50 50 0
NC: non-consensus; number of judges: 12.
Table 11: Outcome of the expert judgement related to criterion 2.1 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.1 (cat. A) The disease is highly transmissible NC 33 67 0
2.1 (cat. B, C) The disease is moderately to
highly transmissible
NC 67 33 0
NC: non-consensus; number of judges: 12.
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Reasoning supporting the judgement
Supporting Yes for 2.1 (cat. A):
• It has caused rapid population crashes in both captive and wild populations.
• Salamanders carrying high-infection loads can spread Bsal infection to na€ıve salamanders
within 2 h of cohousing.
Supporting Yes for 2.1 (cat. B, C):
• It is moderately to highly transmissible according to the host species and the infectious dose.
• Within certain wetlands, if animals have close contact, the transmissibility can be very high. A
different situation occurs between separated wetlands, where the disease has lower
transmissibility, due to the segregation of amphibian population.
Reasoning supporting the judgement
Supporting Yes:
• Bsal infection leads to a lethal, ulcerative skin disease with high mortality and a clear welfare
impact.
• Morbidity is high in some species of European caudata, the salamander population in at least
three MSs is affected, so it could be considered a large number of animals.
Supporting No:
• The number of affected animals is not large considering that Bsal has been detected in few
locations in Belgium (5), Germany (3) and Netherlands (7).
3.3.2. Outcome of the assessment of criteria in Annex IV for
Batrachochytrium salamandrivorans for the purpose of categorisation as
in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 5–9. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
With respect to different type of impact where the assessment is divided into current and potential
impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’ and, in case of
no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for Bsal for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 13.
Table 12: Outcome of the expert judgement related to criterion 5(b)(CI) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5b The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
NC 83 17 0
NC: non-consensus; number of judges: 12.
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According to the assessment here performed, Bsal complies with the following criteria of the
Sections 1–5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment Bsal complies with criteria 2.2, 2.3 and 2.4 and
the assessment is inconclusive on compliance with criteria 1 and 2.1. To be eligible for
category A, a disease needs to comply additionally with one of the criteria of the second set
(3, 4, 5a–d) and Bsal complies with criteria 5b, 5c and 5d, but not with criteria 3, 4 and 5a.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment Bsal complies with criteria 2.2 and 2.3, but not
with criterion 2.4 and the assessment is inconclusive on compliance with criteria 1 and 2.1.
To be eligible for category B, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and Bsal complies with criteria 5b, 5c and 5d, but not with
criteria 3, 4 and 5a.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment Bsal complies with criteria 1, 2.2 and 2.3, but
not with criterion 2.4 and the assessment is inconclusive on compliance with criterion 2.1. To
be eligible for category C, a disease needs to comply additionally with one of the criteria of
the second set (3, 4, 5a–d) and Bsal complies with criteria 5b, 5c and 5d, but not with
criteria 3, 4 and 5a.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, with which Bsal
complies.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which Bsal complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
Bsal. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
Table 13: Outcome of the assessment of criteria in Annex IV for Batrachochytrium salamandrivorans
for the purpose of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.3 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for Bsal according to the criteria of
Article 8(3) of the AHL are as displayed in Table 14.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
Table 14: Main animal species to be listed for Batrachochytrium salamandrivorans according to
criteria of Article 8 (source: data reported in Section 3.1.1.1)
Class Order Family Common names (Genus/Species)
Susceptible Amphibia Caudata Salamandridae Fire salamander (Salamandra salamandra), Alpine
newt (Ichthyosaura alpestris), smooth newt
(Lissotriton vulgaris), North African ﬁre salamander
(Salamandra algira), Corsican ﬁre salamander
(Salamandra corsica), Near Eastern ﬁre salamander
(Salamandra infraimmaculata), Macedonian crested
newt (Triturus macedonicus), marbled newt
(Triturus marmoratus), Eastern newt
(Notophthalmus viridescens), rough-skinned newt
(Taricha granulosa), Italian newt (Lissotriton italicus),
Northern crested newt (Triturus cristatus), spectacled
salamander (Salamandrina terdigitata), yellow-
spotted newt (Neurergus crocatus), Sardinian
mountain newt (Euproctus platycephalus), Chioglossa
spp., Lyciasalamandra spp., Mertensiella spp.,
Ommatotriton spp., Paramesotriton spp.,
Hypselotriton spp.
Plethodontidae Northern slimy salamander (Plethodon glutinosus)
Caudata Plethodontidae French cave salamander (Speleomantes strinatii)
Salamandridae Iberian ribbed newt (Pleurodeles waltl), Tylototriton
spp., Cynops spp.
Reservoir Amphibia Caudata Salamandridae Japanese ﬁre belly newt (Cynops pyrrhogaster),
sword-tailed newt (Cynops ensicauda), Vietnamese
crocodile newt (Tylototriton vietnamensis), black
knobby newt (Tylototriton asperrimus), Chiang Mai
crocodile newt (Tylototriton uyenoi), Tam Dao
salamander (Paramesotriton deloustali), Alpine newt
(Ichthyosaura alpestris)
Hynobiidae Siberian salamander (Salamandrella keyserlingii),
clouded salamander (Hynobius nebulosus), Japanese
clawed salamander (Onychodactylus japonicus)
Caudata Salamandridae Ziegler’s crocodile newt (Tylototriton ziegleri)
Anura Alytidae Midwife toads (Alytes obstetricans)
Vectors None
3 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors, the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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• According to the assessment here performed, Bsal complies with all criteria of the ﬁrst set and
with two criteria of the second set and therefore can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, Bsal meets the criteria as in Sections 4 and 5 of
Annex IV of the AHL, for the application of the disease prevention and control rules referred to
in points (d) and (e) of Article 9(1) of the AHL. According to the assessment here performed, it
is inconclusive whether Bsal complies with the criteria as in Section 1 of Annex IV of the AHL,
for the application of the disease prevention and control rules referred to in point (a) of Article
9(1) of the AHL. Compliance of Bsal with the criteria as in Section 1 is dependent on a decision
on criteria 1 and 2.1.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for Bsal according to Article 8(3) of the AHL are species of the families Salamandridae
and Plethodontidae as susceptible and reservoirs, as reported in Table 14 in Section 3.4 of the
present document.
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Abbreviations
AHL AHLAnimal Health Law
Bsal Batrachochytrium salamandrivorans
Bd Batrachochytrium dendrobatidis
CFSPH Center for Food Security and Public Health
CITES Convention on International Trade in Endangered Species
DGHT Deutsche Gesellschaft f€ur Herpetologie und Terrarienkunde
DSe diagnostic sensitivity
DSp diagnostic speciﬁcity
GE genomic equivalents
ICBA Individual and Collective Behavioural Aggregation
IUCN International Union for Conservation of Nature
MS Member States
OIE World Organisation for Animal Health
qPCR quantitative polymerase chain reaction
ToR Terms of Reference
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